Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Vogelzang says he and his colleagues believe that radium-223 can be combined safely with all hormonal and immune therapies. In one study, radium-223 was given with chemotherapy and researchers found that less chemotherapy had to be administered. Currently, Vogelzang notes, the FDA recommends that radium-223 should not be given with chemotherapy.